NEW YORK, Sept. 2, 2021 /PRNewswire/ -- Seelos
Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage
biopharmaceutical company focused on the development of therapies
for central nervous system disorders and rare diseases, announced
today the appointment of Margaret
Dalesandro, Ph.D. to its Board of Directors.
Dr. Margaret Dalesandro is an
accomplished biopharmaceutical executive with over 30 years of
experience in drug development and commercialization. She held
senior executive leadership positions at ImClone Systems, Inc. and
in her role as Vice President of Project, Portfolio and Alliance
Management, she managed the successful development of ERBITUX
(cetuximab), which contributed significantly to the $6.5 billion sale of ImClone to Eli Lilly and
Company in 2008. Prior to ImClone Systems Inc., Dr. Dalesandro
served as an Executive Director of Cardiovascular/Oncology
Project/Portfolio/Alliance Management at GlaxoSmithKline plc.
Earlier in her career, she was Director of Cardiovascular Research
and Assistant Director of Immunobiology Research and Development,
Pharmaceutical Division, at Centocor, Inc. where her research
contributed to the successful development of REMICADE
"Margaret brings an enormous amount of drug development and
commercialization experience to Seelos," said Raj Mehra, Ph.D.,
Chairman and CEO of Seelos. "We expect significant contributions
from her as we proceed with late-stage development of several of
our assets in the clinic."
She is the founder and currently president of Brecon Pharma
Consulting LLC, a full-service pharmaceutical and biotechnology
consultancy focused on identifying and obtaining critical
information early in product development.
Dr. Dalesandro holds M.A. and Ph.D. degrees in Biochemistry from
Bryn Mawr College and completed an NIH
Postdoctoral fellowship in Molecular Immunology at Wake Forest University. Dr. Dalesandro is Chair of
the Board of Directors of OncoSec Medical Incorporated and a member
of the Board of Directors of Skye Bioscience, Inc.
About Seelos Therapeutics:
Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical
company focused on the development and advancement of novel
therapeutics to address unmet medical needs for the benefit of
patients with central nervous system (CNS) disorders and other rare
diseases. The Company's robust portfolio includes several
late-stage clinical assets targeting indications including Acute
Suicidal Ideation and Behavior (ASIB) in Major Depressive Disorder
(MDD) or Post-Traumatic Stress Disorder (PTSD), Amyotrophic
lateral sclerosis (ALS), Sanfilippo syndrome, Parkinson's Disease,
other psychiatric and movement disorders plus orphan diseases.
For more information, please visit our website:
https://seelostherapeutics.com, the content of which is not
incorporated herein by reference.
Forward Looking Statements
Statements made in this press release, which are not historical
in nature, constitute forward-looking statements for purposes of
the safe harbor provided by the Private Securities Litigation
Reform Act of 1995. These statements are based on management's
current expectations and beliefs and are subject to a number of
factors and uncertainties that could cause actual results to differ
materially from those described in the forward-looking statements.
All information in this press release is as of September 1, 2021 and we undertake no duty to
update this information. A more complete description of these risks
can be found in our filings with the Securities and Exchange
Commission, including our Annual Report on Form 10-K for the
year-ended December 31, 2020 and our
Quarterly Report on Form 10-Q for the quarter-ended June 30, 2021.
Chief Communications Officer
Seelos Therapeutics, Inc. (Nasdaq: SEEL)
300 Park Avenue
New York, NY 10022
View original content to download
SOURCE Seelos Therapeutics, Inc.